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Analytical technologies for influenza virus-like
particle candidate vaccines: challenges and
emerging approaches
Christine M Thompson1,2, Emma Petiot1, Alexandre Lennaertz1,2, Olivier Henry2 and Amine A Kamen1,2*
Abstract
Influenza virus-like particle vaccines are one of the most promising ways to respond to the threat of future
influenza pandemics. VLPs are composed of viral antigens but lack nucleic acids making them non-infectious which
limit the risk of recombination with wild-type strains. By taking advantage of the advancements in cell culture
technologies, the process from strain identification to manufacturing has the potential to be completed rapidly and
easily at large scales. After closely reviewing the current research done on influenza VLPs, it is evident that the
development of quantification methods has been consistently overlooked. VLP quantification at all stages of the
production process has been left to rely on current influenza quantification methods (i.e. Hemagglutination assay
(HA), Single Radial Immunodiffusion assay (SRID), NA enzymatic activity assays, Western blot, Electron Microscopy).
These are analytical methods developed decades ago for influenza virions and final bulk influenza vaccines.
Although these methods are time-consuming and cumbersome they have been sufficient for the characterization
of final purified material. Nevertheless, these analytical methods are impractical for in-line process monitoring
because VLP concentration in crude samples generally falls out of the range of detection for these methods. This
consequently impedes the development of robust influenza-VLP production and purification processes. Thus,
development of functional process analytical techniques, applicable at every stage during production, that are
compatible with different production platforms is in great need to assess, optimize and exploit the full potential of
novel manufacturing platforms.
Keywords: Influenza virus-like particles (VLPs), Quantification, Process Analytical Technologies, Total particles,
Vaccines
Introduction
The World Health Organization (WHO) reports ap-
proximately 500 million cases of influenza infection and
between 250,000 to 500,000 deaths annually due to sea-
sonal epidemics [1,2]. To combat the persistent threat of
influenza epidemics, vaccination remains the most effi-
cient strategy to prevent infection. Since the 1950s, egg-
based production processes remain the standard method
to produce seasonal influenza inactivated whole, split,
subunit or live-attenuated vaccines. The influenza H1N1
pandemic of 2009 has clearly highlighted the limitations
of the current egg-based production methods in the case
of the emergence of a pandemic strain [3,4]. The main
drawback is the relatively long 6-month period from
strain isolation to final dose formulation and validation
[5]. Moreover, in 2006, WHO published an action plan
to increase the current supply of influenza vaccine. One
of the goals was to reach 2340 million monovalent doses
produced in case of a global pandemic, which highlights
the need to develop new technologies capable to support
urgent and large demands for vaccines [6]. As a result,
strategies to shorten the response time for vaccine
preparation and to expand production capacity are in-
creasingly being investigated. Cell culture derived sea-
sonal influenza vaccines are gaining attention and in
November 2012, the first seasonal influenza vaccine
manufactured using cell culture technology (Flucelvax,
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Novartis) was approved by the FDA [7] for adults 18
years of age and older. Very recently, in mid-January
2013, the first trivalent influenza vaccine made using an
insect virus (baculovirus) expression system and recom-
binant DNA technology, Flublok (Protein Science Cor-
poration), was approved for the prevention of seasonal
influenza in people 18 through 49 years of age [8]. These
recent approvals reflect an important trend in the vac-
cine industry of adopting modern cell culture manufac-
turing technologies. This strategy is clearly supported by
the public health and regulatory agencies that invested
massively over the last five years to promote more ad-
equate responses to emerging infectious disease.
Many other strategies, such as subunit or DNA vac-
cines [9], have taken advantage of cell culture and mod-
ern recombinant DNA developments to overcome the
limitations of egg-based production, but one of the most
promising approach is the recombinant based virus-like
particle (VLP) vaccine [10,11].
Influenza virus-like particles are non-infectious and
non-replicating particles, displaying intact and biochem-
ically active antigens required for induction of both
humoral and cellular immune responses [12]. Influenza
VLPs do not contain genetic material, but rather are
empty particles composed of one or both of the two viral
immunogenic activators of influenza: Hemagglutinin
(HA) and Neuraminidase (NA) [11]. In some cases, in-
fluenza VLPs are also constructed with one of the two
influenza matrix proteins, either M1 or M2 [10,12,13].
Unlike other DNA based strategies, the presence of NA
in influenza VLP constructions is one advantage of this
technology, as this antigen was demonstrated to partici-
pate in the host protection against influenza infection
[14,15].
Different production strategies have been investigated
for influenza VLPs. They vary according to the viral
strain, the type of gene delivery utilized and the nature
of the host-cell expression system. Currently, influenza
VLPs are produced in mammalian, insect or plant cell
cultures using a variety of vectors and gene delivery
techniques [16-18]. Table 1 lists key studies describing
the various production methods used to generate influ-
enza VLPs, along with the quantification and purification
strategies employed.
Thus far, immunizations with influenza VLPs to pro-
tect against either seasonal or pandemic influenza strains
have shown promising results [13,31,32]. A general de-
scription of the different immunization trials performed
thus far is presented in Kang et al. 2009 [33]. Now that
proof-of- concept has been established with influenza
VLPs as a vaccine candidate, the next step involves the
development and scale-up of robust manufacturing pro-
cesses to provide clinical trials with vaccine doses.
Process development and clinical trials are both strongly
dependent on the capacity to efficiently characterize and
quantify the vaccine candidate using validated methods
that are accepted by regulatory agencies. Unfortunately,
as detailed in this review, there is still an unmet need for
reliable analytical approaches accounting for the intrin-
sic characteristics of influenza VLPs.
Characterization and quantification methods are nee-
ded at different stages during manufacturing process de-
velopment. Optimization and scale-up generally require
rapid, reliable and easy to set-up methods in order to
screen a large number of operating conditions. For that
reason, the methods in-use should be able to tolerate
crude material of each step of a process. Past studies
have been essentially focused on the immunogenicity of
VLPs as vaccine candidates, with little attention paid to
process analytical technology. While most of these inves-
tigations have applied standard influenza methods to
analyze purified VLP material, quantification methods
that can tolerate in-process samples are becoming a ne-
cessity to support emerging studies focused on the de-
velopment of VLP production processes.
Presently there are no total particle quantification
methods for influenza VLPs other than estimation by a
correlation between the red blood cell hemagglutination
assay (HA assay) and total number of influenza particles
[34]. Antigen based influenza virus quantification
methods (i.e. HA assay, NA assay, SRID) to date have
been used on VLPs to characterize purified end product,
not to assess process conditions and aid optimization.
The applicability of these methods (background, level of
detection, level of quantification) in upstream and down-
stream unpurified samples has not been explored for in-
fluenza VLPs, but studies from influenza virus
production in MDCK cells have been completed with
in-process samples for both the HA and NA assays
[1,35].
Therefore, the goal of this review is to present the dif-
ferent challenges researchers face regarding appropriate
quantification techniques for influenza VLP vaccines.
Specifically, the need for a robust total particle quantifi-
cation technique that can analyze upstream and down-
stream samples, the applicability of current influenza
quantification methods to assist VLP process develop-
ment and, with regards to available technologies, what
could be proposed for future developments. As a sum-
mary, Table 2 presents a comparison of current and fu-
ture methods available for influenza-VLP quantification.
Current influenza VLP quantification methods
Quantification methods for influenza vaccine formula-
tions can be categorized into two general classes. The
first provides information on antigen quantity, usually
in the form of amount of HA in the vaccine dose
(SRID, HA assay) or of enzymatic NA activity, but no
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Table 1 Examples of influenza virus-like particle production
Influenza viral
protein
Influenza strain DNA vector
system
Cell expression
platform
Purification Characterization
quantification
Ref
HA,NA, M1, M2 A/Udorn/72 (H3N2) rBV Sf9 insect cells Partial purification and
concentration by
ultracentrifugation/
Iodixanol and sucrose
gradient
ultracentrifugation
EM/WB/SDS Page [19]
HA (H2/H7/H5)
NA, M1
A/Indonesia/05/2005(H5N1) rBV Sf9 insect cells Sucrose step gradient
ultracentrifugation
EM/Quantitative-WB/
SDS Page/SRID assay/
Hemagglutination assay
[20]
A/Swine/Missouri/4296424/
2006 (H2N3)
A/New York/107/2003 (H7N2)
A/Viet Nam/1203/2004 (H5N1)
HA, NA, M1 A/HongKong/1073/99 (H9N2) rBV Sf9 insect cells Partial purification and
concentration by
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/Quantitative WB/SDS
Page/Neuraminidase
activity/Hemagglutination
assay
[13]
HA, M1 A/Puerto Rico/8/1934 (H1N1) rBV Sf9 insect cells Partial purification and
concentration by
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/WB/SDS Page/
Hemagglutination assay
[21]
A/WSN/33
HA, NA, M1 A/Fujian/411/2002 (H3N2) rBV Sf9 insect cells Sucrose gradient
ultracentrifugation/Ion-
exchange
chromatography
EM/WB/SDS Page/TBA
Neuraminidase assay/
Hemagglutination assay/
SRID assay
[22,23]
A/Indonesia/5/2005 (H5N1)
HA, M1 HA: A/California/04/2009
(H1N1)
rBV Sf9 & BTI-TN5B1-4
insect cells
Partial purification and
concentration by
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/Quantitative WB/SDS
Page/Hemagglutination
assay
[16]
M1: A/Udorn/307/1972 (H3N2)
NA A/Cambodia/JP52a/2005
(H5N1)
pCDNA
plasmid
HEK 293T –
HeLa – A549
mammalian cells
Partial purification and
concentration by
sucrose cushion
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/Quantitative WB/SDS
Page/NA Star
Neuraminidase assay
[24]
HA, NA, NP, M1,
M2, NS2, PB1,
PB2, PA
A/Udorn/72 (H3N2) pCAGGS
plasmid
HEK 293T & HeLa
mammalian cells
Partial purification and
concentration by
sucrose cushion
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/Quantitative WB/
SDS Page/VLP infectivity
assay (transfer of GFP-
expressing pseudogene)
[25]
HA, NA, M2 A/Chicken/FPV/Rostock/1934
(H7N1)
MLV GagPol HEK 293T & TE671
human cells
Partial purification and
concentration by
sucrose cushion
ultracentrifugation
Quantitative WB/SDS
Page
[26,27]
A/Thailand/KAN-1/04 (H5N1)
HA, NA, M1 A/Vietnam/1203/2004 (H5N1) rMVA vector Vero monkey cells Partial Purification and
concentration by
filtration with 100kDa
molecular weight cut
off/Sucrose gradient
ultracentrifugation
EM/WB/SDS Page/
Hemagglutination assay
[28]
A/Puerto Rico/8/1934 (H1N1)
HA, NA, M1 A/Puerto Rico/8/1934 (H1N1) rBV HEK 293T human
cells
Partial purification and
concentration by
sucrose cushion
ultracentrifugation/
Sucrose gradient
ultracentrifugation/
Precipitation by
ultracentrifugation
BCA Total protein assay/
WB/SDS Page/
Hemagglutination assay
[17]
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commercial vaccine exists with controlled NA. Even
though these methods have the ability to provide infor-
mation on the quantity, functional properties and en-
zymatic activity of antigens in vaccine doses, they do not
directly provide information on how these antigens will
elicit an immune response. This is done after vaccin-
ation and virus challenge with collected sera coupled
with HA inhibition and/or NA inhibition tests. Acknow-
ledging that this is a specific problem that applies to
both influenza virus and influenza VLP quantification of
final vaccine formulations it will not be further discussed
in the following subsections. The other quantification
type gives information on whole viral particles, specific-
ally, the total number of particles (qPCR) or the number
of infectious particles (Plaque Assay, TCID50).
Quantification of influenza VLPs can also be divided
into these two categories; antigen based and whole par-
ticle based methods. Antigen based methods are rou-
tinely used for the quantification of purified VLP end
products, however total particle quantification by qPCR
cannot be used for VLP quantification due to their lack
of genome. As previously mentioned, there is a relation-
ship between the HA assay and the number of influenza
particles that could be used to estimate VLP total par-
ticle titers, but this correlation has some caveats that will
be discussed. In the following sections, methods that are
currently used to quantify and characterize influenza
VLPs will be described and discussed in more detail
when applied in the context of process development.
Single radial immunodiffusion (SRID)
Current human influenza vaccine doses are determined
from the only validated potency test, the single radial
immunodiffusion (SRID) assay. SRID remains the only
method to date that has been approved by the WHO au-
thorities for the quantification of HA protein in trivalent
influenza vaccines [51]. This method provides an estima-
tion of the antigenicity of the preparation as it is based
on standard antigens. It works by measuring the radial
diffusion of the viral antigens in an agarose gel con-
taining specific antibodies. In contrast to the hemagglu-
tination assay (described next), this method measures
the HA content expressed in μg of HA/ml. It generally
has a limit of detection of approximately 3–5 μg/ml [36].
Medicago Inc. is currently undergoing pre-clinical and
clinical trials with their plant based influenza VLP candi-
date against A/California/2009, which has been quanti-
fied using the SRID method [52].
Over the years, several limitations of this test have
been described in the literature. Firstly, non-aqueous
vaccine components can interfere with the diffusion of
the HA antigen in the agarose gel [53]. This can pose a
significant challenge for quantifying VLPs in unpurified
samples taken at different stages during production and
purifications steps. Secondly, this method requires a long
processing time, has a low sensitivity and needs updating
to the homologous HA antigen references and their
specific monoclonal antibodies every year [43,54,55]. In
the case of a pandemic, this annual update might result
in prolonged delays that would prevent rapid vaccine
availability. Thirdly, HA protein is prone to aggregation.
This effect is particularly relevant for concentrated prep-
arations because high concentrations of influenza viral
particles were shown to be more susceptible to aggregate
formation [56]. Large aggregates may prevent proper
diffusion and interfere with readings. To address these
challenges, WHO is encouraging research groups
and pharmaceutical industries to develop alternative
methods that can provide rapid and reproducible results
and replace SRID-based quantification [6]. This is
targeted to influenza virus-derived vaccines but could be
transposed to VLP vaccines as well. In the case of VLPs
however, this method does not resolve the pressing issue
of needing a quantification method that can handle in-
process material.
Hemagglutination assay
The hemagglutination assay (HA assay) was the first
method proposed to quantify the influenza virus based
on its agglutination property [37]. After some modifi-
cations from Salk, the method has remained largely
unchanged and has been applied for the determination
of HA activity in viral preparations [57,58]. The activi-
ty measurement is based on the observation of the
Table 1 Examples of influenza virus-like particle production (Continued)
HA, M1 A/Indonesia/5/05 (H5N1) rAgrobacterium N. benthamiana
plant cells
Centrifugation/Affinity
chromatography
EM/WB/SDS Page/Total
protein analysis Lipid
analysis/
Hemagglutination assay
[29]
A/New Caledonia/20/99
(H1N1)
HA, NA, M1, M2 A/Taiwian/083/2006 (H3N2) pC14 plasmid Vero monkey cells Partial purification and
concentration by
sucrose cushion
ultracentrifugation/
Sucrose gradient
ultracentrifugation
EM/WB/SDS Page/Total
protein analysis/
Hemagglutination assay/
Dynamic Light
Scattering/LC-MS/MS
[12,30]
A/Hanoi/30408/2005 (H5N1)
Associated expression system, quantification and purification applied (rBV, Recombinant baculovirus; MLV, Murine Leukemia Virus).
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Table 2 Potential or in-use quantification methods for influenza virus-like particles
Quantification
method
Used with
flu-VLPs
Sample
type
LOD LOQ Working Range SD (%RSD) Assay
Duration
Ref
HA antigen SRID Yes P, NP, ~3 μg/ml ~3 μg/ml 3.12 – 100 ug/ml (10%) ~30 h [36]
HA assay Yes P, NP 2 HA unit/50ul 2 HA unit/50ul 2 - 2048 HA units/50 μl ~0,066 % ~5 h [37,38]
LC-MS No P 25 fmol 25 fmol 25 - 400fmol/10ul (H1): 1.14 (3.5%) n.s. [39,40]
(H3): 1.24 (5.6%)
(B): 5.04 (9.7%)
RP-HPLC Yes V (H1): 0.25 ug/ml (H1): 0.75ug/ml 2.5-100ug/ml 3.58 % 10-20 min [41]
(B): 1 ug/ml (B): 3ug/ml 7.73%
Universal ELISA No V 1ug/ml 0.2-16ug/ml 0.14-0.3 (14 - 30%) n.s. [42]
SPR immuno
assays
No P, NP, V <0.5ug/ml 1ug/ml 1-15ug/ml n.s. n.s. [43]
NA antigen TBA NA assay Yes P 0.34 mU/ml 1.03 mU/ml 0.54 -6.47 mU/ml 2.95% n.s. [35]
NA star assay Yes P, NP 3 pM 3pM 3-10.5nM n.s. ~1.5 h [44]
Amplex Red NA
assay
Yes P 2.09 mU/ml 6.32mU/ml 2.00-7.00 mU/ml 16% [35]
NA-Fluor Assay Yes P, NP 0.09 mU/ml 0.17-2.00 mU/ml n.s. 2.55% ~4 h [35]
HA & NA antigen LC-MS No V n.s. n.s. NA: 2-12ug/ml n.s. ~5 h [39]
HA: 10-70ug/ml
Universal SlotBlot No V, rHA, rNA 0.032 ug/ml 0.032 ug/ml HA: 0.032-3ug/ml 2300 - 13500 (5%)
particles/count
n.s. [14,45]
NA: 0.037-10 ug/ml
Total particles DLS No P, NP 8.6 × 101
TCI50units/ml
8.6 × 101 TCI50units/ml 8.6 × 101 to 3.4 × 104
TCID50units/ml
n.s. <30min [46]
Virus Counter No P, NP (NP): 3.6 × 106 VP/ml (NP): 3.6 × 106 VP/ml 105 - 109 VP/ml 0.09 +/− 0.03 VP/ml ~40 min [47]
(P): 1.0 × 105 VP/ml (P): 1.0 × 105 VP/ml
AFFFF-MALS No P, NP n.s. n.s. 5 × 108 - 4.5 × 109 VP/ml n.s. ~1 h [48-50]
Type of samples: P, Purified; NP, Non-purified; V, Vaccine doses; N.s, Non specified.
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agglutination of red blood cells (RBCs) by the HA pro-
tein. Donald and Issacs established by quantification of
viral particles with electron microscopy and based on
the red blood cell (RBC) concentration that there is ap-
proximately one influenza virus for each red blood cell
at the end point of agglutination [34]. Although this
assay is not considered a standard method by health au-
thorities, many production and purification yields of
influenza-VLPs were evaluated using this technique in
the literature (see Table 1).
The principle of this assay is simple, but its prepar-
ation is laborious and presents some drawbacks. The red
blood cells have to be fresh to obtain reproducible re-
sults and their agglutination properties decline over
time. Each supply of erythrocyte is different in origin, so
assay standardization with an external standard is neces-
sary at each trial. This constitutes a major problem for
VLPs, due to the current lack of such standard. No
standard protocol is followed for this assay either, as dif-
ferent erythrocyte cell types have been used such as
turkey [17], chicken [59] or human [16] at concentra-
tions ranging from 0.5-1.25%. Additionally for wild-type
viruses, the host-origin and the influenza strain affect
the hemagglutination reaction with the RBCs. Further-
more, this can affect the ratio between total particles
and red blood cells as shown by Issacs and Donald [60].
When the virus/RBC = 1 theory was expanded to other
viruses containing hemagglutination properties; a dis-
crepancy in the ratio with Influenza C, filamentous in-
fluenza virus and the mumps virus was observed. The
explanation for this lies in the agglutination ability of
these specific viruses. Viruses with increased agglutin-
ation ability i.e., increased amount of HA on the particle
surface, have a virus to RBC ratio lower than one. Con-
versely, those with reduced agglutination ability have a
ratio higher than one. It has been largely assumed that
influenza-VLPs will be morphologically similar to influ-
enza viruses produced in cell culture (spherical in shape,
80–120 nm in size) [12,29,59,61,62]. From electron mi-
croscopy images of influenza VLPs produced in our lab,
we observed different populations sizes from 100nm to
400nm (data not shown). These VLPs could exert en-
hanced or reduced agglutination abilities, changing the
ratio of VLP to RBC and leading to an under or overesti-
mation for total influenza VLPs. Therefore, to estimate
production yield compared to influenza in terms of units
of total particles, this method could be useful, but to ac-
curately quantify, more studies need to be completed on
the specific relationship between VLPs and RBCs at the
agglutination end point.
Another constraint of this assay for VLP quantification
is related to the required concentration and purity of the
samples, which can limit its applicability for high
throughput use during process development. Non-
purified samples could give false positives from free pro-
tein and contaminating particles from the production
system used, as illustrated in Table 3. Table 3 presents
the HA titers in mammalian vs. insect cell produced
VLPs. For VLPs produced in insect cells, HA was
detected in culture supernatants at a level 25 times
higher than mammalian VLPs and 4 times less than in-
fluenza virus A/PR/8/1934. The main difference between
VLP production in mammalian vs. insect cells is the
presence of residual baculovirus in the insect cell system
[63]. Baculovirus is an enveloped virus that simultan-
eously buds during VLP production in insect cells and
take up HA protein in its viral envelope [64]. The HA
assay is unable to differentiate between HA activity from
influenza VLPs and HA activity from baculovirus
displayed with HA. Thus giving enhanced HA activity
readings and total particle estimation. This also poses a
problem for other types of VLP quantification. On the
Table 3 Comparison of HA assay response from VLPs produced in Mammalian and Insect cells and chicken egg derived
influenza virus
Production System Influenza strain Sample preparation HA titer Contamination Normalized
Concentration
(HA units/ml)
VLPs from Sf9 - baculovirus
infection [16]
HA:A/California/07/2009 (H1N1) Cell culture media 16 HA units/50 μl baculovirus
108 BV/ml
16 HA units/50 μl
M1:A/Udorn/307/1972 (H3N2)
VLPs from HighFive -
baculovirus infection [16]
HA:A/California/07/2009 (H1N1) Cell culture media 16 HA units/50 μl baculovirus
106 BV/ml
16 HA units/50 μl
M1:A/Udorn/307/1972 (H3N2)
VLPs from HEK 293 T - plasmid
transfection [17]
HA/NA/M1: A/Puerto Rico/8/34
(H1N1)
Purified VLPs
concentrated 200 times
32 HA units/50 μl none 0.16 HA units/50 μl
VLPs from HEK 293 T -
baculovirus transduction [17]
HA/NA/M1 Purified VLPs
concentrated 200 times
128 HA units/50 μl none 0.64 HA units/50 μl
A/Puerto Rico/8/34 (H1N1)
Influenza virus Chicken Eggs [59] H1N1 A/PR/8/1934 Purified virus 256 HA units/50 μl none 256 HA units/50 μl
This is a rough comparison, as each system used a different source of red blood cells (chicken, turkey, human) at different percentages (0.5-1.25%).
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contrary, mammalian produced VLPs avoid the problem
of baculovirus contamination by using either transient
transfection or the bacmam system for VLP production.
Nevertheless, for this case, the assay sensitivity is
questioned for quantifying supernatant. Mammalian
VLP productions had to be concentrated 200 times to
reach measurable titers of 32 HA units/50 ul, consider-
ing the limit of detection for this technique is 2 HA
units/50 ul (Table 2). Additionally, false negatives could
arise if sample concentration is not taken into consider-
ation when analyzing supernatants from VLP produc-
tions in different production systems. All this
information illustrates the main constraint with using
the HA assay to aid process development, susceptibility
to false positives and insufficient limit of detection.
Enzymatic NA activity assay
Another approach for VLP quantification specifically ap-
plies to those VLPs that include the viral glycoprotein
neuraminidase (NA). During a regular infection cycle
NA acts as an enzyme that is specifically responsible for
the release of viral particles from the cell. Several NA ac-
tivity assays are commercially available and have been
used to evaluate VLPs. VLPs have been tested previously
for NA activity using the classic colometric thiobar-
bituric acid (TBA) method [13,59], a chemilumines-
cence-based assay using the 1,2-dioxetane derivative of
sialic acid as a substrate (NA- star Influenza Inhibitor
Resistance Kit, Invitrogen) [24], and two different fluoro-
metric methods (Amplex Red Neuraminidase Assay Kit,
Invitrogen) [59] and FL-MU-NANA [65]. Nayak et al.
[35] compared different NA assays; TBA, Amplex red
and FL-MU-NANA for their ability to quantify in-
process crude samples during influenza production in
MDCK cells. They found the FL-MU-NANA method to
be the most robust with low background in crude sam-
ples and high sensitivity, allowing for NA detection as
low as 0.09 mU/ml and quantification as low as 0.26
mU/ml, with a range of linearity of 0.17 - 2.00 mU/ml.
As an aside, supernatant samples were diluted 4–100
times before assaying. On the other hand, the NA-star
system reports 67-fold higher sensitivity [44] compared
to the FL-MUNANA system, albeit the NA activity ex-
periments were completed with purified material and
the authors report that this method may not be suitable
with cell culture media due to interference from the
quenching effects of phenol red. Wen et al’s study of
VLPs produced in insect cells has shed some light re-
garding the level of NA activity in VLPs vs. influenza
virus; A/PR/8/1934 had 4 times the amount of NA activ-
ity of VLPs, which agrees with the levels from the HA
assay of Sf9 VLPs vs. influenza virus [59]. Considering
that in Nayak et al’s study the virus samples were diluted
4-100 times [35], the FL-MUNANA method has the
potential for monitoring NA activity levels in crude and
in-process VLP productions. However to date, no studies
have been done on this application.
Total protein analysis
Total protein analysis (protein assays, densitometry by
silver stain/coomassie blue and western blot) detect all
the proteins present in a sample, which may also include
proteins from the host-cell, medium or other viral vector
proteins such as those from baculovirus. Due to the lack
of specificity, these techniques can only be used for sam-
ples containing purified material and do not qualify for
use during process development with crude samples.
However, they could be good qualitative methods to
evaluate the final production yield and purity. Analysis
of purified VLPs was usually performed with SDS-PAGE
/Western Blot (WB) to determine the presence of spe-
cific influenza proteins [22,59]. The relative percentage
of antigens in purified VLP samples from Sf9 insect cells
showed a composition of 15% HA by coomassie blue
staining and 12% by western blot. NA and M1 proteins
were seen by coomassie blue, but not measured by
densitometry [59]. Mammalian H5N1 VLPs reported
22% and 10.9 % of HA and NA, respectively, for the
relative abundance of total VLP proteins [30] by
coomassie blue staining measured by densitometry. In
another study by Wu et al., using LC-MS/MS they iden-
tified 22 VLP associated host cell proteins commonly
found in the interior or exterior of influenza virus parti-
cles [12]. The LC-MS/MS method and its applicability
for VLP quantification will be discussed further in the
following section. Protein assays are frequently described
in the literature for the quantification of purified VLPs
as illustrated in Table 1. D’Aoust et al. demonstrated
80% purity of plant derived VLP produced purified by
size exclusion chromatography [29]. Additionally, pro-
tein assays such as the bicinchoninic acid (BCA) assay
[17] or the Quant-IT assay kit with bovine serum albu-
min (BSA) [12] were used to quantify the total protein
content in purified samples.
Electron microscopy (TEM)
Historically, electron microscopy (EM) has been widely
used for virus observation and has already been applied
to influenza whole virus quantification [34,60]. Up to
this point, EM has been used to verify the presence and
characterize influenza VLPs in terms of morphology and
size of the particles [13,16,28].
The main constraints of this technique are sample prep-
aration complexity, the price of equipment and level of ex-
pertise needed to analyze and run samples. Moreover, as
microscopy counts are based on visual enumeration, sam-
ples should be pure enough in order to distinguish the
particles, thereby also making this method unsuitable for
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the analysis of crude samples collected upstream and
downstream. Besides contamination from cellular debris,
some production strategies have to face contamination
with other types of particles, either other viruses used as a
gene delivery vectors (i.e baculovirus), aggregates of influ-
enza proteins or vesicles produced by the host cell that
may be present in purified material [63]. Currently, there
is no other option to validate the physical presence of
VLPs in a highly purified sample.
Potential novel methods for influenza VLP quantification
This section critically reviews the most promising novel
analytical approaches with regards to the potential of
these techniques to analyze in-process samples for both
antigen and physical particle counts. These techniques
were used for quantification of either influenza whole-
virus or other VLP associated viruses. Technologies
based on physical properties instead of biological activity
of either antigen or particles are good options in order
to have generic, rapid and reproducible VLP quantifica-
tion. Additionally, they usually have lower limits of de-
tection and broader range of analysis than biological
methods, with better selectivity and sensitivity. Potential
methods to quantify total particles, such as Dynamic
Light Scattering (DLS), Asymmetric Field-Flow Fraction-
ation Using Multi- Angle Light Scattering Detection
(AFFFF-MALS); Electrospray Differential Mobility (ES-
DMA) and a flow cytometry method (using the Virus
Counter) will be discussed for their application to VLPs.
For methods dedicated to quantify HA or NA antigens,
liquid-chromatography based methods (Reverse Phase
High Pressure Liquid Chromatography (RP-HPLC), Li-
quid Chromatography with Tandem Mass Spectrometry
(LC-MS/MS)) are a valuable option, but biological activ-
ity is still an important aspect to assess. Immunoassays
such as ELISA, Slot Blot, and Surface Plasmon Reson-
ance (SPR) evaluate biological activity and will be further
discussed in this section. These methods have the poten-
tial to analyze samples from a variety of different matri-
ces and concentrations, such as those during process
development. However, more development and valid-
ation for their successful application to influenza VLP
quantification is still needed.
Methods based on antigen detection
Liquid chromatography methods
Reversed-phase high performance liquid chromatog-
raphy (RP-HPLC) RP-HPLC approach to quantify the
hemagglutinin content in influenza vaccines is a very pro-
mising technique. It has been investigated since 2006 by
two research groups; the Center of Vaccine Evaluation,
Health Canada and Solvay Biologicals [41,53,66,67]. Both
methods developed quantify the HA1 subunit of HA. Dif-
ferent sample treatments to release HA1 were evaluated,
but both groups found the best sample treatment was
a two-step process. It includes treatment with deter-
gent (Zwittergent 3–14) to solubilize membrane pro-
teins followed by treatment with a reducing agent
(dithiothreitol, DTT) to break the disulfide bounds
between HA1 and HA2 subunits [53]. The method
was proven to be efficient for quantification of all the
16 HA subtypes from A and B strains [53], for both
seasonal and pandemic virus [67]. It is able to handle
both egg and cell culture-derived samples [53], but
presently its use is limited to the final vaccine formu-
lation or purified material. However, different types of
final formulation were tested, and the inactivation agent
seems to have an impact on the chromatograms obtained.
β-propiolactone creates peak interferences, which changed
the retention time (RT) and the peak width of the HA1
subunit whereas formaldehyde-inactivated samples did
not show any peak deviation [53].
According to the authors, the method showed high
sensitivity. Depending on the strain analyzed, the limit
of detection (LOD) could be as low as 0.25 μg/ml of HA
which is about 12 times lower than the LOD of SRID
assay. The main advantage of this method holds in its
fast analysis time and its potential to be used at all
process stages, pre- and post-purification.
This method also presents a significant advantage over
other techniques, as it can distinguish, in trivalent vac-
cine formulations, HA content from each HA subtypes
in a single analysis (i.e the amount of HA in H1N1 vs.
H3N1) based on the retention time [41,53,66]. Kapteyn
et al. showed that H1, H3 and B subtypes eluted respect-
ively at 4.8 min, 3.7 min, and 3.2 min. Differences in
HA1 retention time were recently attributed to primary
structure and glycosylation differences [53].
The type of detection method used also seems to be of
importance with regards to sensitivity. Kapteyn et al.
show a response of 100 times higher when detecting
with a fluorescence (FLD) wavelength (λ = 335nm) com-
pared to UV absorption at a wavelength of 215nm. This
is of great importance considering the constraint of low
production yields observed for influenza-VLP produc-
tions. With both detection methods, response intensity
was dependent of the influenza strain of origin for HA1.
This is most likely related to the variation in amino acid
composition of different HA subtypes. It has been
shown that the presence of large amounts of aromatic
amino acids such as tryptophan and tyrosine as well as
the associated sites of O- and N-glycosylation can mod-
ify the signals [53,66].
Reverse-Phase HPLC is a valuable method to imple-
ment at the stage of the process optimization and scale-
up for influenza VLP production; however, it has to be
kept in mind that this method is only quantifying the
amount, or mass, of HA protein present in the sample.
Thompson et al. Virology Journal 2013, 10:141 Page 8 of 14
http://www.virologyj.com/content/10/1/141
Although it has already been considered by regulatory
authorities as an alternative method to pre-qualify pan-
demic vaccine lots while the SRID antibodies and stan-
dards were still being generated (personal
communication with Health Canada and WHO repre-
sentatives), assessing the antigenicity of vaccine prod-
ucts, through SRID or other anti-HA antibodies binding
assays, will still be required for release of clinical influ-
enza vaccine lots.
LC-MS methods Recently, LC-MS and LC-MS/MS
methods have demonstrated the ability to quantify both
HA and NA content in influenza vaccine formulations
from different origins, egg- or plant-derived [39,40].
Evaluation of the LC-MS/MS method was performed on
different sample types, including seasonal trivalent influ-
enza vaccines containing H1N1, H3N2 and B strains,
monovalent pandemic vaccines, vaccine bulk prepara-
tions and recombinant antigens. The method was de-
scribed as rapid, providing quantification of all protein
components in a single analytical procedure, and above
all, did not depend on the availability of specific anti-
bodies or standard antigens [39]. The principle lies on
analyzing the mass and charge of peptides generated
from protein trypsinization. To quantify the amount of
target protein, the combined signal from the three most
intense peptides is compared against an internal stand-
ard. Limits of detection and of quantification are 1 μg of
HA or NA protein, which falls in the lower range of the
quantification methods previously discussed. Williams
et al. [40] argue that this level could be as low as 150pg
of protein when considering classic levels of detection
for LC-MS/MS.
Similarly to HPLC-based methods, this method does
not measure the immunogenic activity of the HA anti-
gen such as the SRID method. Therefore, it can only be
used as a method to quantify antigen content in vaccine
formulations. One of the interesting points of this study
is the discrepancies highlighted when compared to vac-
cine doses measured by SRID for different strains in the
seasonal vaccine formulations. The SRID method
reported HA levels three times higher than HA protein
content quantified by the LC-MSE (LC-MS with an ele-
vated energy acquisition method) physical direct
method. These results clearly demonstrate the failure of
SRID standardization method.
The authors cite critical factors on which the method’s
success depends. One critical factor is to insure that
trypsin digestion is performed at its maximum capacity
and that sufficient quantity of protein is available to re-
lease a detectable amount of tryptic peptides. This is a
very important roadblock with regards to VLPs quantifi-
cation considering the low production levels achieved
thus far.
Another issue is the composition of the sample matrix.
Obviously, purified material is the ideal material to work
with, avoiding interference with contaminant proteins
from the cell culture supernatant. When LC-MS/MS
was used for influenza virus vaccine doses produced
from eggs it was able to identify and quantify up to 19
μg contaminant protein/vaccine dose. A method that is
able to quantify both protein of interest and contami-
nants at the same time has a clear advantage over other
methods from a regulatory standpoint. Nevertheless, it
also shows that sample matrix will have a strong effect
on the number of peptides identified.
Immunoassays
The identification of universal antibodies against HA
and NA proteins has been an important breakthrough
for quantification techniques based on biological activity.
A recent development for the Slot Blot and ELISA as-
says, which aims to develop a method that can analyze
all current and new circulating strains of influenza, is
very promising for the quantification of influenza pro-
teins and VLPs. Rabbit polyclonal antibodies have been
raised against highly conserved regions of all the sub-
types of influenza A and B hemagglutinins and neur-
aminidases [14,42]. In the case of HA, universal
antibodies were raised against a sequence of 11 amino
acids in the N-terminal region of HA2. This amino acid
sequence is the most broadly conserved region among
all influenza A subtypes [42]. For NA, the regions se-
lected were located either (i) close to the enzymatic site
of NA (ILRTQESEC), or (ii) in the cytoplasmic tail at
the N-terminal of the neuraminidase (MNPNQKIITIGS)
[14]. Universal antibodies raised against HA2 were found
to detect one B strain and the 13 different subtypes of A
influenza strains while universal antibodies raised against
the NA conserved regions reacted against the 9 subtypes
of NA, in both avian and human influenza strains.
The use of these antibodies for in-process samples has
not been validated yet for production with cell culture
based systems but no cross-reactivity with egg proteins
was observed for uninfected or infected allantoic fluids
[14,42]. Additionally, universal antibodies are also able
to detect recombinant proteins produced in insect-cells.
Enzyme-linked immune sorbent assay (ELISA) Based
on the anti-HA universal polyclonal antibody, a com-
petitive ELISA assay was recently published [42]. Au-
thors demonstrate that the new quantification method
of both recombinant HA and human vaccine provided
very similar values to those obtained by the SRID
assay. This method is very promising for future vac-
cine candidate development especially in the case of fu-
ture pandemic vaccines. However, it still needs further
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development to define LOD and LOQ to be able to com-
pare with traditional SRID assay.
Slot-blot Another quantification technique based on
universal recognition of HA or NA antigens, is the Slot
blot technique [45,68]. The authors argue in favor of this
technique by presenting it as a simple, highly reliable, in-
expensive and easy to operate technique. The procedure
is fast, only taking 5 h. However, this assay was far less
documented than the proposed techniques previously
cited. No indication of the precision or repeatability of
the method was provided. Consequently, at that stage, it
is still not possible to compare its efficiency compared
to classic neuraminidase enzymatic activity techniques
or the SRID assay.
Surface Plasmon Resonance Immunoassay (SPR) The
surface plasmon resonance (SPR) was also proposed as
an alternative to the SRID assay [43]. This technology
has been originally commercialized under the name of
Biacore® [69]. The principle is based on the competitive
binding of specific anti-HA antibodies between HA pro-
tein present in the sample and rHA protein coated on
the gold biosensor surface. The signal measured is in-
versely proportional to the concentration of HA protein
content in the sample. An influenza quantification with
SPR technology using low affinity ligands, e.g., lectins or
specific carbohydrate structures, such as sialic acids
that bind HA protein on the biosensor surface was
tested [70]. This technique was abandoned due to low
limit of detection and then was further developed using
antibodies. However, it might be advantageous to pursue
the development of this approach using a ligand binding
system that “recognizes” different influenza virus strains
eventually leading to a more universal method.
This technology offers higher sensitivity in different
types of sample matrices and precision than the SRID
method, with a limit of detection as low as 0.5 μg/ml for
A/H3N2 Wisconsin/67/2005, A/H1N1/Solomon Islands/
3/2006 and B/Malaysia/2506/2004 strains [43] and limit
of quantification of 1 μg/ml. The specificity of the sera
from sheep origin for the recombinant protein used was
tested, and the authors found that the responses were
specific to their matching recombinant protein type with
no cross reactivity. However, serum from chicken A/
H1N1/PR/1934 was non- specific and bound to each re-
combinant protein matrix. Samples were analyzed with
the Biacore® at different stages of the vaccine purification
process, from cell culture supernatant harvest to ultra/
dia-filtrated samples [43]. It was found that the Tween
20 surfactant contributed to prevent adsorption of pro-
teins to the matrix and HA aggregation. Increasing
sucrose (>1%) and NaCl (>0.2M) concentrations resul-
ted in a decreased response, thereby increasing the
calculated amount of HA present in the sample. For in-
process VLP samples this shouldn’t pose a problem, but
for partially or fully purified samples by either sucrose
cushion and gradient ultracentrifugation or chromatog-
raphy that routinely have higher levels of sucrose and
NaCl greater than 20% and 0.5M, respectively, lower re-
sponses might be observed.
Methods based on total particle quantification
Virus counter (cytometry) A focused flow cytometry
method [71], the Virus Counter has recently been pro-
posed as a method to quantify total virus particles. Pre-
vious studies have been completed with influenza virus
[47]. The basic analytical principle exploited in the Virus
Counter relies on flow cytometry and fluorescence de-
tection. The Virus Counter uses a non-virus specific dye,
Combo Dye, which stains proteins (red) and nucleic
acids (yellow). It is equipped with software that quanti-
fies intact virus particles, those that emit orange fluores-
cence, which contain both labeled proteins and nucleic
acids. This dye is advantageous compared to traditional
antibody labeling techniques that can be laborious and
expensive. Additionally, it solves the problem of the re-
quirement for specific strain influenza antibodies that
impede vaccine development. This method has a quick
and simple sample preparation and runtime, which in-
cludes 30 minutes incubation with the dye at room
temperature and 10 minutes analysis time. Stepp et al
[47] compared quantification by the Virus Counter to
qPCR for total particle determination of H1N1 A/Cali-
fornia/2009 and also to the manufacturer’s TCID50 and
TEM values. They found that all values correlated sig-
nificantly with each other. Ferris et al. completed a simi-
lar study for baculovirus quantification, comparing the
Virus Counter to the plaque assay (PFU) method using
non-purified material [72]. They found the limit of de-
tection increased approximately 1 log when using non-
purified samples. While there have been no studies done
with VLPs to date, the Virus Counter seems to be a
promising method for VLP quantification during process
development considering its low limit of quantification
even in non-purified samples. However, because the sys-
tem has been set up for virus quantification, the dye and
software is tailored for labeling and detecting virus sam-
ples (protein + nucleic acid). While this system could still
provide information on the quantity of VLPs that con-
tain host cell derived nucleic acids, a concern for regula-
tory agencies, quantification could be inaccurate if it
does not include protein-only detection. Therefore, ei-
ther the software would need to be adapted for VLP
quantification or the method used to label VLPs
changed, potentially labeling NA or HA proteins with
red and yellow fluorescent tagged antibodies. This would
bring up the problem of strain specific antibodies, so
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staying with a generic labeling system with adapted soft-
ware would be the most beneficial to address the need
of total particle quantification for VLP process develop-
ment and final product characterization.
Size-based techniques
Dynamic light scattering (DLS) with gold
nanoparticles Light scattering technologies, measuring
the size, the aggregation and the zeta potential of parti-
cles has already been evaluated for the detection and
quantification of different viruses or VLPs [46,73-75].
Wu et al and Pincus et al. used DLS to analyze the aver-
age size of purified influenza VLPs, but not to quantify
total particles [12,51]. One recent paper has applied this
technique to influenza detection [46]. The principle is
based on influenza specific antibodies conjugated with
gold nanoparticles (AuNP) used as probes. The aggrega-
tion between these probes and the virus is measured by
DLS technology, and the mean hydrodynamic diameter
(DH) of the formed aggregates is correlated to virus con-
centration. AuNP light scattering is highly efficient com-
pared to light scattering from biomolecules [76,77]
therefore when coupled with specific binding to VLPs
this method presents the possibility of high sensitivity
with low background, even with crude samples. How-
ever, a level of background from contaminating particles
from the production system such as vesicles or baculo-
virus would have to be established. The detection limit
is 1–2 folds lower than the traditional infectious particle
count technique, TCID50 assay, with a value of 8.6 × 101
TCI50 units/ml, with an increase in DH with increasing
concentration of influenza up to 3.0 × 104 TCID50 units/
ml. DH decreases at concentrations higher than 3.0 ×
104 TCID50 units/ml from a phenomena known as the
hook effect [78]. Above this concentration, the virions
are in excess of AuNP, resulting in a decreased mean
DH. One important consideration for this method is that
the antibody chosen for conjugation to AuNP must be
able to bind to whole intact virus, or VLP, and not re-
gions that are only exposed after particle disruption or
protein cleavage (i.e. the conserved stalk region of HA2).
Another is the presence of contaminating particles from
the production system such as vesicles that could alter
the mean DH. AuNP probe concentration and size also
have an impact on the technique detection limit and
would need to be optimized for influenza VLP applica-
tion. A comparison of detection of influenza viruses pro-
duced in eggs or MDCK cells proved that the technique
is not sensitive to change in the sample matrix. There-
fore, DLS is a promising technique to fulfill the lack of
total particle count in the case of influenza VLPs and
could have the potential to be used to process develop-
ment with upstream and downstream samples. However;
again it still needs be optimized further as this paper
does not present any values of quantification errors and
a calibration curve with quantified VLPs would need to
be established.
Asymmetric flow field-flow fractionation using
multi-angle light scattering detection (AFFFF-MALS)
AFFFF is another size-based technique to separate parti-
cles. In this case, the range considered is 1 nm to 100
um. The standard detector used is UV at 280nm, but if
it is coupled with a multi-angle light scattering (MALS)
detector selectivity could be further increased [48]. The
principle is complex but is well described by Pease et al
[49]. Briefly, hydrated virus particles are injected into a
separation channel containing a porous membrane along
the bottom of its surface. Fluid enters the channel,
spreading the particles along its width, while liquid is
evacuated through the porous membrane. Particle elu-
tion is then performed with laminar flow across the
channel while a cross-flow is maintained through the
membrane. This allows for small particles to elute into
the laminar flow channel before large particles. In order
to elute remaining large particles and aggregates, cross-
flow is stopped thus releasing them into the laminar flow
channel.
AFFFF-MALS was successfully applied to H1N1,
H3N2 and B influenza strains [50] with both crude and
purified material from egg-based production. The range
of linearity obtained for B/Yamanashi/166/98 influenza
viral strain was of 5 × 108 to 4.5 × 109 VP/ml. One of the
main problems occurring when choosing a size detection
method for quantifying influenza virus is particle aggre-
gation. By optimizing the equation model, Mc Evoy et al.
[48] managed to reach values in very good agreement
with TEM for the quantification of a B/Yamanashi/166/
98 influenza viral strain (2.2 × 1010 VP/ml & 1.6 × 1010
VP/ml, respectively). The technique also compared the
EM and qPCR for total particle counts, and TCID50 or
fluorescent focus assay (FFA) [49,50] for infectious
counts. Considering the similarity between values
obtained by AFFF-MALS and the EM-based method, it
is possible to envisage this technique as a reliable, and
cost-effective tool to quantify content of total particles
in virus and virus-like particle preparations. However,
the equipment needed and high level of technicality re-
quired still impedes the routine use of this method.
Electrospray differential mobility analysis (ES-DMA)
The principle of virus quantification from differential
mobility analysis (DMA) is analogous to mass spectrom-
etry, which separates peptides on a charge-to-mass ratio,
while with DMA particles are separated and analyzed by
an ion mobility analyzer on the basis of charge-to-size
ratio [79]. Particle separation is completed in the gas-
phase after aerosolization of the samples. The particle
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detection is done either by transmission electron micros-
copy or with a particle counter after real-time condensa-
tion of separated fractions of the samples. The technique
is able to separate particles of sizes ranging from
sub-nanometer (proteins), to intact viral particles (25-
300 nm). To date 21 different types of virus have been
assessed with this method. Most of them were non-
enveloped viruses, but three enveloped viruses have been
successfully analyzed, the Sendai rodent virus, alpha
virus, and the murine hepatitis virus. This method has
never been applied to influenza virus itself, but it was re-
cently applied to polyomavirus VLPs carrying 17 resi-
dues of HA protein from avian influenza strain [49,79].
The main advantage of the ES-DMA technique is the
wide linearity range, reaching five orders of magnitude
in some cases, with low limits of detection and of quan-
tification (108 VP/ml for phage PP7). It is also able to
provide a size distribution of the viral particles, detecting
some changes of 0.3 nm [80]. In the case of VLPs, be-
yond just quantifying the number of particles,
characterization of the particles could be of great inter-
est for the field. Consequently, even though it has mostly
been developed for non-enveloped small size viruses (20
nm) this technique is a potential interesting tool for
influenza-VLP quantification and characterization.
Nevertheless, at this stage of development of the
method, there are still some drawbacks such as the com-
plexity of operation, and the expertise and equipment
required. Another drawback for the application of this
technology to influenza-VLP is the challenging step of
electrospraying enveloped virus. Optimizing the best op-
eration conditions for this step is still a matter of trial
and error as quantitative and theoretical models to de-
scribe the impact of electrohydrodynamic forces on
lipids envelopes are not yet available [80].
Conclusion
Until now VLP studies have been completed with the
final goal of evaluating their potential as vaccine candi-
dates. Therefore, the current methods available for influ-
enza vaccine quantitation have been sufficient for
concentrated and purified final material. However, as
more research is done on influenza VLPs through the
lens of bioprocessing for industrial applications; it has
become obvious that these methods are deeply impeding
the development of manufacturing processes. Not only
do they come with problems already associated with in-
fluenza quantification (lack of universal standard and a
direct total quantification method), they are also labori-
ous and cannot be applied for analysis of in-process
samples. Potential quantification methods for both anti-
gen and total particles were presented in this review that
fulfills most of these needs (low limit of detection, in-
process use). For some of them the main drawback
remains their complexity of operation, which is not ne-
cessarily compatible with an application for process
monitoring or process development phases. Neverthe-
less, we are on the way to develop usable techniques that
are compatible with different production platforms and
applicable for process development and optimization
studies for influenza VLPs.
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